ArticleNature2021
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.
0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
10.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 193 citations in OpenAlex.
- The Developmental and Functional Implications of Age-Associated B Cells (ABCs) Across Tissue Microenvironments.Immunological reviews · 2026Review
- Infection of Rhesus Macaques with O'nyong-nyong virus UVRI-0804 recapitulates key aspects of human clinical disease.PLoS neglected tropical diseases · 2026Article
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- A MICA/B GAALIE-mutant antibody elicits potent natural killer cell-driven immunity in solid and hematologic malignancy models.Cell reports. Medicine · 2026Article
- Fc-engineered antibodies enhance protection against SARS-CoV-2 lung infection and inflammation.mBio · 2026Article
- Prefusion-stabilized SARS-CoV-2 spike reshapes antigenic hierarchy and antibody targeting against conserved and occluded epitopes.NPJ vaccines · 2026Article
- Determinants of natural killer cell-mediated antibody dependent cellular cytotoxicity in SARS-CoV-2 antibodies.PLoS pathogens · 2026Article
- SARS-CoV-2 antibody-dependent enhancement of infection depends on antibody binding to both ACE2 and Fc receptors.JCI insight · 2026Article
- Development of a potent monoclonal antibody for treatment of human metapneumovirus infections.Nature communications · 2026Article
- T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy.medRxiv : the preprint server for health sciences · 2026Article
- Innovation in active and passive immunisation of people who are immunocompromised: a call to action.The Lancet. Infectious diseases · 2026Review
- Fc effector functions in RNA viral infections: mechanisms of antiviral immunity and implications for vaccine design.Frontiers in immunology · 2026Review
- Determinants of success and failure of antibody-based strategies against respiratory viruses: insights from RSV and SARS-CoV-2.Frontiers in immunology · 2026Review
- Review
- Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials.Virology journal · 2025Article
- Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates.NPJ vaccines · 2025Article
- FcγRIIIa is a noncanonical costimulatory molecule for CD8 T cells.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Induction of lung mucosal immunity by a next-generation inhaled aerosol COVID-19 vaccine: an open-label, multi-arm phase 1 clinical trial.Nature communications · 2025Article
- Light Chain Isotype and Antibody-Specificity Impact on Virus Neutralization.Antibodies (Basel, Switzerland) · 2025Article
- BNT162b2 COVID-19 vaccination elicits the expansion of CD16The Journal of allergy and clinical immunology · 2025Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
11 authors at 2 institutions in 1 country.
Rachel Yamin *Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.
Andrew T Jones *Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-3739-2322
Hans-Heinrich HoffmannLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-0554-0244
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kevin S KaoLaboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.
Rebecca L FrancisLaboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.
Timothy P SheahanDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-9181-2183
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-6827-8701
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-3087-8079
Jeffrey V RavetchLaboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA. ravetch@rockefeller.edu.ORCID http://orcid.org/0000-0003-2024-9041
Stylianos BournazosLaboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA. sbournazos@rockefeller.edu.ORCID http://orcid.org/0000-0001-5466-5620
Rockefeller University · USUniversity of North Carolina at Chapel Hill · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MUnderstanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI WANG, TAIA · 2014 to 2023
$26.0MEvaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infectionR01AI145870 · NIAID · ROCKEFELLER UNIVERSITY · PI Peter Palese, JEFFREY Victor RAVETCH · 2019 to 2026
$8.4MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MMechanisms of antibody-dependent enhancement of SARS-CoV-2 infectionR01AI137276 · NIAID · ROCKEFELLER UNIVERSITY · PI Stylianos Bournazos · 2018 to 2026
$4.5MNCI NIH HHS P30 CA008748NIAID NIH HHS R01 AI137276NIAID NIH HHS R01 AI145870NIAID NIH HHS R01 AI157155NIAID NIH HHS U19 AI111825
Abstract
Monoclonal antibodies with neutralizing activity against SARS-CoV-2 have demonstrated clinical benefits in cases of mild-to-moderate SARS-CoV-2 infection, substantially reducing the risk for hospitalization and severe disease
Indexed as
COVID-19 Drug TreatmentAnimalsAntibodies, MonoclonalAntibodies, NeutralizingCOVID-19CricetinaeDisease Models, AnimalFemaleHumansImmunoglobulin Fc FragmentsImmunoglobulin GMaleMicePre-Exposure ProphylaxisReceptors, IgGSARS-CoV-2Antibodies, MonoclonalAntibodies, NeutralizingImmunoglobulin Fc FragmentsImmunoglobulin GReceptors, IgG
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.